J. R. Fozard (1982). Highly potent irreversible inhibitors of aromatic L-amino acid decarboxylase.
Trends Pharmacol.Sci. 3 : 429.
J. Gerlach, L. Peacock (1995). New antipsychotics: the present status. Int. J. Psychopharmacol.
10 : 39.
M. Goldstein, D. B. Calne, A. Lieberman, M. O. Thorner (1980). Ergot Compounds and Brain
Function. New York: Raven Press.
A. Hilditch, G. M. Drew (1985). Peripheral dopamine receptor subtypes—a closer look. Trends
Pharmacol. Sci. 6 : 396–400.
O. Hornykiewicz (1977). Psychopharmacological implication of dopamine antagonists: a critical
evaluation of current evidence. Annu.Rev. Pharmacol.Toxicol. 17 : 545–549.
S. D. Iversen (1986). Psychopharmacology. Oxford: Oxford University Press.
J. Jankovic (1999). New and emerging therapies for Parkinson’s disease. Arch. Neurol. 56: 785.
M. D. Jibson, R. Tandon (1998). New atypical antipsychotic medications.J. Psychiatr. Res. 32 : 215.
I. Jirkovsky, W. Lippman (1978). Antidepressants. Annu.Rep. Med. Chem. 13: 1–10.
J. M. Kane (1996). Schizophrenia. New Engl. J. Med. 334: 445.
J. M. Kane (1999). Pharmacologic treatment of schizophrenia. Biol. Psychiatry 46: 1396.
M. Kapsimali, S. Le Crom, P. Vernier (2003). A natural history of vertebrate dopamine receptors.
Neurol. Dis. Ther. 56: 1–43.
J. W. Kebabian, T. Agui, J. C. van Oene, K. Shigematsu, J. M. Saavedra (1986). The D 1 dopamine
receptor: new perspectives. Trends Pharmacol. Sci. 7: 96–99.
W. C. Koller, E. Tolosa (1998). Current and emerging drug therapies in the treatment of
Parkinson’s disease. Neurology 50(Supplement 6): 1–65.
A. E. Lang, A. M. Lozano (1998). Parkinson’s disease. New Engl. J. Med. 339: 1044.
J. W. Langston (1985). Mechanism of MPTP toxicity: more answers, more questions. Trends
Pharmacol. Sci. 6 : 375–378.
T. A. Larsen, D. B. Calne (1985). Recent advances in the study of Parkinson’s disease. In:
D. Bousfield (Ed.). Neurotransmitters in Action. Amsterdam: Elsevier, pp. 252–256.
H. Y. Meltzer (1999). Treatment of schizophrenia and spectrum disorders: pharmacotherapy,
psychosocial treatments, and neurotransmitter interactions. Biol. Psychiatry 46: 1321.
J. C. Nelson (1997). Treatment of refractory depression. Depress. Anxiety 5: 165.
C. B. Nemeroff, S. T. Cain (1985). Neurotensin–dopamine interaction in the CNS. Trends
Pharmacol. Sci. 6: 201–205.
K. A. Neve, C. J. DuRand, M. M. Teeter (2003). Structural analysis of the mammalian D2, D3,
and D4 dopamine receptors. Neurol. Dis. Ther. 56 : 77–144.
A. G. Phillips, R. F. Lane, C. D. Blaha (1986). Inhibition of dopamine release by cholecystokinin:
relevance to schizophrenia. Trends Pharmacol. 7 : 126–127.
N. P. Quinn (1984). Anti-Parkinson drugs today. Drugs 28: 236–262.
J. M. Schaus, J. A. Clemens (1985).Dopamine receptors and dopaminergic agents. Annu. Rep.
Med. Chem. 20: 41–50.
P. G. Strange (1986). Isolation and characterization of D 1 dopamine receptors. Trends Pharmacol.
Sci. 7: 253–254.
C. A. Tamminga (2002). Partial dopamine agonists in the treatment of psychosis. J. Neural
Transmission 109: 411–420.
E.-K. Tan (2003). Dopamine agonists and their role in Parkinson’s disease treatment. Exp. Rev.
Neurotherap. 3: 805–810.
R. Tintner, J. Jankovic (2003). Dopamine agonists in Parkinson’s disease. Exp. Op. Inv. Drugs 12:
1803–1820.
P. Tyrer, A. Mackay (1986). Schizophrenia: no longer a functional psychosis. Trends Neurosci. 9:
537–538.
NEUROTRANSMITTERS AND THEIR RECEPTORS 303